Figure 1.
Figure 1.

Flow chart outlining the timeline of study events that occurred at timepoints 0, 24, and 144 h. Treatment with either meloxicam at 1 mg/kg or a placebo was administered at time 0 h after baseline blood sample collection. Follow-up blood sample collection for determination of biomarkers and drug concentrations occurred after a 16 h (1,316 km) transportation event and 120 h thereafter.

 


Figure 2.
Figure 2.

Mean ± SE for BW change (kg) after treatment with 1 mg/kg meloxicam or a placebo at 0 h followed by a 16 h (1,316 km) transportation event. Letters that are the same indicate data points that are not significantly different (P < 0.05).

 


Figure 3.
Figure 3.

Mean ± SE for serum cortisol concentrations after treatment with 1 mg/kg meloxicam or a placebo at 0 h followed by a 16 h (1,316 km) transportation event. Letters that are the same indicate data points that are not significantly different (P < 0.05).

 


Figure 4.
Figure 4.

Mean ± SE for plasma log haptoglobin (Hp)-matrix metalloproteinase-9 (MMP-9) complexes concentrations after treatment with 1 mg/kg meloxicam or a placebo at 0 h followed by a 16 h (1,316 km) transportation event. Letters that are the same indicate data points that are not significantly different (P < 0.05).

 


Figure 5.
Figure 5.

Mean ± SE for serum tumor necrosis factor-α (TNFα) concentrations after treatment with 1 mg/kg meloxicam or a placebo at 0 h followed by a 16 h (1,316 km) transportation event. Letters that are the same indicate data points that are not significantly different (P < 0.05).

 


Figure 6.
Figure 6.

Mean ± SE for plasma substance P concentrations after treatment with 1 mg/kg meloxicam or a placebo at 0 h followed by a 16 h (1,316 km) transportation event. Letters that are the same indicate data points that are not significantly different (P < 0.05).

 


Figure 7.
Figure 7.

Mean ± SE for circulating neutrophil counts after treatment with 1 mg/kg meloxicam or a placebo at 0 h followed by a 16 h (1,316 km) transportation event. Letters that are the same indicate data points that are not significantly different (P < 0.05).

 


Figure 8.
Figure 8.

Mean ± SE for circulating lymphocyte counts after treatment with 1 mg/kg meloxicam or a placebo at 0 h followed by a 16 h (1,316 km) transportation event. Letters that are the same indicate data points that are not significantly different (P < 0.05).

 


Figure 9.
Figure 9.

Mean ± SE for circulating monocytes counts after treatment with 1 mg/kg meloxicam or a placebo at 0 h followed by a 16 h (1,316 km) transportation event. Letters that are the same indicate data points that are not significantly different (P < 0.05).